Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Fatigue in CIDP

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

09:29 MIN

CIDP

Engage in a presentation on the comparison between active and remission disease states in CIDP.

DOWNLOAD PDF

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

12:13 MIN

CIDP

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

DOWNLOAD PDF

IgG Levels and Wear Off Reflect Administration and Outcome

Carol L. Koski, MD

GBS/CIDP Foundation International

5:51 MIN

CIDP
GBS

Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.

DOWNLOAD PDF

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

3:00 MIN

CIDP
MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF

NOW PLAYING

09:29

Fatigue in CIDP

Engage in a presentation on the comparison between active and remission disease states in CIDP.

NOW PLAYING

12:13

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabiliza...

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

NOW PLAYING

5:51

IgG Levels and Wear Off Reflect Administration and Outcome

NOW PLAYING

3:00

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Our Experts on CIDP

VIEW ALL EXPERTS

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

CIDP
MMN

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.

Carol L. Koski, MD

GBS/CIDP Foundation International

Carol L. Koski, MD

GBS/CIDP Foundation International

CIDP
GBS

Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?